Kaisi Kaidi Pharmaceutical Technology

Cascade, established in December 2017, is a Sino-foreign joint venture biomedical enterprise specializing in the development of innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs). The company's core research and development (R&D) team is led by internationally renowned structural biologists and top nuclear receptor scientists, boasting over 20 years of experience in innovative drug research. Cascade focuses on addressing critical health issues such as metabolic diseases, tumors, and inflammation through structure-based drug design. The company operates in the biomedical sector, primarily serving healthcare providers, pharmaceutical companies, and research institutions. Cascade's business model revolves around the discovery, development, and commercialization of novel therapeutic drugs. Revenue is generated through partnerships, licensing agreements, and direct sales of their proprietary drugs.

Keywords: innovative drugs, nuclear receptors, GPCRs, metabolic diseases, tumors, inflammation, structure-based design, biomedical, Sino-foreign joint venture, R&D.